Johnson & Johnson: Continue to believe in positive benefit-risk profile of COVID-19 vaccine

“We continue to believe in a positive benefit-risk profile of COVID-19 vaccine,” Johnson & Johnson (J&J) said in response to the statement released after the US Centers for Disease Control and Prevention (CDC) Advisory Committee meeting.
J&J said that it has actively postponed the launch of its vaccine in Europe.
Earlier on, the US CDC extended the halt on the distribution of the vaccine amid a lack of more data to assess the risk.
Market reaction
The risk sentiment remains upbeat despite the J&J covid vaccine concerns, with the S&P 500 futures gaining 0.10% to 4,120, at the time of writing.
The US dollar index wallows in multi-week lows, as the sell-off extends into Asia.
Author

Dhwani Mehta
FXStreet
Residing in Mumbai (India), Dhwani is a Senior Analyst and Manager of the Asian session at FXStreet. She has over 10 years of experience in analyzing and covering the global financial markets, with specialization in Forex and commodities markets.

















